Found: 71
Select item for more details and to access through your institution.
A Database-driven Decision Support System: Customized Mortality Prediction.
- Published in:
- Journal of Personalized Medicine, 2012, v. 2, n. 4, p. 138, doi. 10.3390/jpm2040138
- By:
- Publication type:
- Article
Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. 8, p. 5299, doi. 10.1002/alz.13893
- By:
- Publication type:
- Article
Tau and amyloid PET associations with impaired sleep and 24‐hour rhythms across aging and neurodegenerative disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.080384
- By:
- Publication type:
- Article
Cortical and substantia nigra <sup>18</sup>F‐PI‐2620 tau PET signal in Lewy body disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.079047
- By:
- Publication type:
- Article
Impact of florbetaben acquisition timing on continuous and dichotomous measures of amyloid burden: implications for real‐world amyloid PET interpretation.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.080405
- By:
- Publication type:
- Article
Impact of florbetaben acquisition timing on continuous and dichotomous measures of amyloid burden: implications for real‐world amyloid PET interpretation.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 10, p. 1, doi. 10.1002/alz.082004
- By:
- Publication type:
- Article
Cortical and substantia nigra 18F‐PI‐2620 tau PET signal in Lewy body disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 10, p. 1, doi. 10.1002/alz.081868
- By:
- Publication type:
- Article
P4‐576: CONCORDANCE BETWEEN 18F‐PI‐2620 TAU PET/MRI IMAGING AND CLINICAL OUTCOMES IN ALZHEIMER DISEASE AND OTHER TAUOPATHIES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1541, doi. 10.1016/j.jalz.2019.08.124
- By:
- Publication type:
- Article
Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain 18F-FDG-PET Scans.
- Published in:
- Journal of Digital Imaging, 2020, v. 33, n. 2, p. 447, doi. 10.1007/s10278-019-00289-x
- By:
- Publication type:
- Article
Multi-task weak supervision enables anatomically-resolved abnormality detection in whole-body FDG-PET/CT.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-22018-1
- By:
- Publication type:
- Article
Predicting FDG‐PET Images From Multi‐Contrast MRI Using Deep Learning in Patients With Brain Neoplasms.
- Published in:
- Journal of Magnetic Resonance Imaging, 2024, v. 59, n. 3, p. 1010, doi. 10.1002/jmri.28837
- By:
- Publication type:
- Article
Increasing Diversity in Radiology and Molecular Imaging: Current Challenges.
- Published in:
- Molecular Imaging & Biology, 2021, v. 23, n. 5, p. 625, doi. 10.1007/s11307-021-01610-3
- By:
- Publication type:
- Article
The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval.
- Published in:
- Molecular Imaging & Biology, 2021, v. 23, n. 4, p. 614, doi. 10.1007/s11307-021-01583-3
- By:
- Publication type:
- Article
Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[<sup>18</sup>F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality.
- Published in:
- EJNMMI Physics, 2018, v. 5, n. 1, p. 1, doi. 10.1186/s40658-018-0207-x
- By:
- Publication type:
- Article
Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders.
- Published in:
- European Journal of Human Genetics, 2007, v. 15, n. 7, p. 779, doi. 10.1038/sj.ejhg.5201831
- By:
- Publication type:
- Article
Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab.
- Published in:
- JAMA Neurology, 2022, v. 79, n. 1, p. 87, doi. 10.1001/jamaneurol.2021.3933
- By:
- Publication type:
- Article
Bridging the Health Data Divide.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A polymorphic polymerase.
- Published in:
- Brain: A Journal of Neurology, 2006, v. 129, n. 7, p. 1637, doi. 10.1093/brain/awl169
- By:
- Publication type:
- Article
Segmenting Cervical Arteries in Phase Contrast Magnetic Resonance Imaging Using Convolutional Encoder–Decoder Networks.
- Published in:
- Applied Sciences (2076-3417), 2023, v. 13, n. 21, p. 11820, doi. 10.3390/app132111820
- By:
- Publication type:
- Article
Early‐onset familial parkinsonism due to POLG mutations.
- Published in:
- Annals of Neurology, 2006, v. 59, n. 5, p. 859, doi. 10.1002/ana.20831
- By:
- Publication type:
- Article
POLG mutations and Alpers syndrome.
- Published in:
- Annals of Neurology, 2005, v. 57, n. 6, p. 921
- By:
- Publication type:
- Article
Prospective Comparison of <sup>68</sup>Ga-NeoB and <sup>68</sup>Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.267017
- By:
- Publication type:
- Article
Prospective Comparison of <sup>68</sup>Ga-NeoB and <sup>68</sup>Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 6, p. 897, doi. 10.2967/jnumed.123.267017
- By:
- Publication type:
- Article
A Pilot Study of <sup>68</sup>Ga-PSMA11 and <sup>68</sup>Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 5, p. 744, doi. 10.2967/jnumed.122.264448
- By:
- Publication type:
- Article
A Pilot Study of <sup>68</sup>Ga-PSMA11 and <sup>68</sup>Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 4, p. 592, doi. 10.2967/jnumed.122.264783
- By:
- Publication type:
- Article
Correlation of <sup>68</sup>Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 12, p. 1829, doi. 10.2967/jnumed.122.263971
- By:
- Publication type:
- Article
<sup>68</sup>Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 12, p. 1822, doi. 10.2967/jnumed.122.263897
- By:
- Publication type:
- Article
Correlation of <sup>68</sup>Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.263971
- By:
- Publication type:
- Article
<sup>68</sup>Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.263897
- By:
- Publication type:
- Article
<sup>68</sup>Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.263897
- By:
- Publication type:
- Article
Correlation of <sup>68</sup>Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.263971
- By:
- Publication type:
- Article
Correlation of <sup>68</sup>Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.122.263971
- By:
- Publication type:
- Article
<sup>68</sup>Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.122.263897
- By:
- Publication type:
- Article
Correlation of <sup>68</sup>Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.122.263971
- By:
- Publication type:
- Article
<sup>68</sup>Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.122.263897
- By:
- Publication type:
- Article
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.259630
- By:
- Publication type:
- Article
Prognostic value of bone marrow metabolism on pretreatment 18 F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.254482
- By:
- Publication type:
- Article
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.259630
- By:
- Publication type:
- Article
Prognostic value of bone marrow metabolism on pretreatment <sup>18</sup>F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy .
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.254482
- By:
- Publication type:
- Article
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.259630
- By:
- Publication type:
- Article
Prognostic value of bone marrow metabolism on pretreatment <sup>18</sup>F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.254482
- By:
- Publication type:
- Article
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.259630
- By:
- Publication type:
- Article
Prognostic value of bone marrow metabolism on pretreatment <sup>18</sup>F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.254482
- By:
- Publication type:
- Article
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.259630
- By:
- Publication type:
- Article
Prognostic value of bone marrow metabolism on pretreatment <sup>18</sup>F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.254482
- By:
- Publication type:
- Article
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 23, doi. 10.2967/jnumed.120.25963
- By:
- Publication type:
- Article
Prognostic value of bone marrow metabolism on pretreatment <sup>18</sup>F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.254482
- By:
- Publication type:
- Article
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.259630
- By:
- Publication type:
- Article
Prognostic value of bone marrow metabolism on pretreatment <sup>18</sup>F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.254482
- By:
- Publication type:
- Article